Read More 1 minute read Clinical News News Tempus Launches Minimal Residual Disease Test Portfolio Key Highlights Clinical launch of MRD test portfolio featuring xM and xM (NeXT Personal® Dx) tests. Tumor-naïve and tumor-informed assays designed for… byChris-Anne RoqueJune 3, 2024